A Phase 2 interventional study of Famotidine and Celecoxib in 2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection and 2019-nCoV Disease, sponsored by Leidos Life Sciences. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-16.
Sponsored by Leidos Life Sciences · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing famotidine in COVID-19 — none open to participants now, 1 under way, none of them phase 3. Famotidine · COVID-19.
Among the 10 studies testing famotidine in COVID-19, this one is the 6th largest by enrollment, is one of 5 that started in 2021, is one of 6 in phase 2, and was the 7th registered.
7,994 studies on the registry are indexed under COVID-19; 467 are open to participants now.
Browse COVID-19 studies →None of the 10 studies testing famotidine in COVID-19 is open now. The open studies under COVID-19, anywhere →
Famotidine: first FDA approval 1986 (PEPCID). What it is approved for, and how studies give it, is on its page →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2020; this study’s year is marked. 5 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 4 is below the median of 102 across 4,366 interventional studies indexed under COVID-19.
Median enrollment 5 across the 10 interventional studies. Of the 6 that completed or were terminated, 3 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 10 have an industry lead sponsor. The 7 most frequent:
Leidos Life Sciences is the lead sponsor of 4 studies on the registry; none are open to participants now.
Leidos Life Sciences has 4 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing famotidine in COVID-19, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This master protocol serves as a common reference for the inpatient and outpatient clinical studies that share common elements.
There are currently two addenda to this master protocol:
Addendum 1, Study LDOS-21-001-01, is a Phase 2, randomized, single-blind, placebo-controlled study to evaluate the safety and efficacy of the combination of famotidine and celecoxib as a treatment in moderate-to-severe patients hospitalized for COVID-19.
Addendum 2, Study LDOS-21-001-02, is a Phase 2 randomized, placebo-controlled, double-blind study to evaluate the safety and efficacy of the combination of famotidine and celecoxib as a post-exposure prophylaxis (PEP) for newly infected COVID-19 patients.
Participants will receive 80 mg famotidine (PO) QID and 400 mg celecoxib as a first dose, followed by 200 mg (PO) BID celecoxib, for 5 days. Following this 5-day period, participants will continue their famotidine treatment for an additional 9 days.
Drug: Famotidine · Drug: Celecoxib
Participants will receive matching placebos QID and BID, for 5 days. Following this 5-day period, subjects will continue to receive matching famotidine placebo, QID, for an additional 9 days.
Other: Placebo
80 mg tablet, QID for 14 days
Also known as: Pepcid
400 mg (initial dose) then 200 mg capsule, BID for 5 days
Also known as: Celebrex
tablet, QID for 14 days; capsule, BID for 5 days
(LDOS-21-001-01) Time-to-event to achieve WHO level ≤3
Evaluation of the time-to-event to achieve a WHO level score ≤3
Time frame: 30 days
(LDOS-21-001-01) All-Cause Mortality rate
Measured in whole numbers by participants removed from the study with reason of "death" in the electronic data capture system
Time frame: 30 days
(LDOS-21-001-02) Number of patients with at least one COVID-19-related medically attended contact due to increased COVID-19 symptom severity
Medically attended contact will be measured in whole numbers and reported as "1 medically attended contact" each time, in the electronic data capture system for all study participants
Time frame: 30 days
(LDOS-21-001-02) Number of patients with at least one COVID-19-related medically attended contact due to death (all-cause mortality)
Medically attended contact will be measured in whole numbers and reported as "1 medically attended contact" in the electronic data capture system for all study participants.
Time frame: 30 days
Plan to share: Undecided — It is not yet known if there will be a plan to make IPD available.
Ran from Dec 2021 to primary completion in Nov 2025, 46 months.
Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 13. This study's 46 months is above that.
Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Famotidine · Celecoxib
Leidos Life Sciences